A. DE BARTOLOMEIS, C. TOMASETTI - Vol. 9, December 2003, Issue 4
Testo Bibliografia Summary Indice
Schizofrenia e disregolazione dopaminergica cortico-sottocorticale:
basi molecolari
e correlati clinici dell’agonismo parziale dopaminergico come strategia
terapeutica
Schizophrenia and dopamine cortico-subcortical dysregulation: molecolar
implication for dopomine partial agonism therapy
1 Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog Brain Res 1998;116:421-37.
2 Grunder G, Wong DF. The next generation of "atypical" antipsychotics: the role of positron emission tomography. Fortschr Neurol Psychiatr 2003;71:415-20.
3 Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000;20:423-51.
4 Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000;31:371-84.
5 Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997;94:2569-74.
6 Carson RE, Breier A, de Bartolomeis A, Saunders RC, Su TP, Schmall B, et al. Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997;17:437-47.
7 Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999;46:56-72.
8 Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-71.
9 Akil M, Pierri JN, Whitehead RE, Edgar CL, Mohila C, Sampson AR, et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 1999;156:1580-9.
10 Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
11 Bertolino A, Knable MB, Saunders RC, Callicott JH, Kolachana B, Mattay VS, et al. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiatry 1999;45:660-7.
12 Meltzer HY, Alphs LD, Bastani B, Ramirez LF, Kwon K. Clinical efficacy of clozapine in the treatment of schizophrenia. Pharmacopsychiatry 1991;24:44-5.
13 Meltzer HY. An atypical compound by any other name is still a. Psychopharmacology (Berl) 2000;148:16-9.
14 Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-46.
15 Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-87.
16 Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 4):90-8.
17 Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Ward JS, Calligaro DO, et al. Potential role of muscarinic receptors in schizophrenia. Life Sci 1999;64:527-34.
18 Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, et al. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane. Eur J Pharmacol 1998;356:109-19.
19 Wadenberg ML, Soliman A, VanderSpek SC, Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001;25:633-41.
20 Kapur S, McClelland RA, VanderSpek SC, Wadenberg ML, Baker G, Nobrega J, et al. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport 2002;13:831-5.
21 Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-6.
22 Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001;158:360-9.
23 Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry 1998;3:135-40.
24 Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Target CNS Neurol Disord 2002;1:141-7.
25 Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002;109:411-20.
26 Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
27 McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002;16:779-86 (discussion 787-8).
28 Clarke WP, Bond RA. The elusive nature of intrinsic efficacy. Trends Pharmacol Sci 1998;19:270-6.
29 Kehr W, Carlsson A, Lindqvist M, Magnusson T, Atack C. Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol 1972;24:744-7.
30 Walters JR, Bunney BS, Roth RH. Piribedil and apomorphine: pre- and post-synaptic effects on dopamine synthesis and neuronal activity. Adv Neurol 1975;9:273-84.
31 Aretha CW, Galloway MP. Dopamine autoreceptor reserve in vitro: possible role of dopamine D3 receptors. Eur J Pharmacol 1996;305:119-22.
32 Ariens EJ. Intrinsic activity: partial agonists and partial antagonists. J Cardiovasc Pharmacol 1983;5(Suppl 1):S8-15.
33 Kenakin T. Drugs and receptors. An overview of the current state of knowledge. Drugs 1990;40:666-87.
34 Pliska V. Partial agonism: mechanisms based on ligand-receptor interactions and on stimulus-response coupling. J Recept Signal Transduct Res 1999;19:597-629.
35 Clark D, Hjorth S, Carlsson A. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 1985;62:171-207.
36 Clark D, Hjorth S, Carlsson A. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 1985;62:1-52.
37 Carlsson A. Dopamine receptor agonists: intrinsic activity vs. state of receptor. J Neural Transm 1983;57:309-15.
38 Roth RH. Dopamine autoreceptors: pharmacology, function and comparison with post-synaptic dopamine receptors. Commun Psychopharmacol 1979;3:429-45.
39 Heidbreder CA, Baumann MH. Autoregulation of dopamine synthesis in subregions of the rat nucleus accumbens. Eur J Pharmacol 2001;411:107-13.
40 Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002;303:815-22.
41 Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002;303:805-14.
42 Zorad S, Golda V, Fickova M, Macho L, Pinterova L, Jurcovicova J. Terguride treatment attenuated prolactin release and enhanced insulin receptor affinity and GLUT 4 content in obese spontaneously hypertensive female, but not male rats. Ann NY Acad Sci 2002;967:490-9.
43 Golda V, Fickova M, Pinterova L, Jurcovicova J, Macho L, Zorad S. Terguride attenuates prolactin levels and ameliorates insulin sensitivity and insulin binding in obese spontaneously hypertensive rats. Physiol Res 2001;50:175-82.
44 Avalos M, Mak C, Randall PK, Trzeciakowski JP, Abell C, Kwan SW, et al. Nonlinear analysis of partial dopamine agonist effects on cAMP in C6 glioma cells. J Pharmacol Toxicol Methods 2001;45:17-37.
45 Asano S, Ueki K, Suzuki I, Kirino T. Clinical features and medical treatment of male prolactinomas. Acta Neurochir (Wien) 2001;143:465-70.
46 Metman LV, Sethy VH, Roberts JR, Bravi D, Hoff JI, Mouradian MM, et al. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson’s disease. Mov Disord 1994;9:577-81.
47 Meltzer HY. Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies. Schizophr Bull 1980;6:456-75.
48 Olbrich R, Schanz H. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmacopsychiatry 1988;21:389-90.
49 Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 1998;43:2-11.
50 Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn J Pharmacol 2001;86:376-80.
51 Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9.
52 Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11.
53 Epstein J, Stern E, Silbersweig D. Mesolimbic activity associated with psychosis in schizophrenia. Symptom-specific PET studies. Ann NY Acad Sci 1999;877:562-74.
54 O’Connor WT. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia. J Neurosci Methods 2001;109:31-9.
55 Tzschentke TM. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 2001;63:241-320.
56 Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105-11.
57 Inoue A, Seto M, Sugita S, Hide I, Hirose T, Koga N, et al. Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res Mol Brain Res 1998;55:285-92.
58 Lidow MS, Song ZM, Castner SA, Allen PB, Greengard P, Goldman-Rakic PS. Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol Psychiatry 2001;49:1-12.
59 Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001;50:729-42.
60 Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248-59.
61 Deutch AY. Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. J Clin Psychiatry 1994;55(Suppl B):37-42.
62 Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271:1058-66.
63 Fink-Jensen A, Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett 1994;182:115-8.
64 Deutch AY, Duman RS. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neurosci 1996;70:377-89.
65 de Bartolomeis A, Aloj L, Ambesi-Impiombato A, Bravi D, Caraco C, Muscettola G, et al. Acute administration of antipsychotics modulates Homer striatal gene expression differentially. Brain Res Mol Brain Res 2002;98:124-9.
66 Polese D, de Serpis AA, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology 2002;27:906-13.
67 Semba J, Sakai M, Miyoshi R, Mataga N, Fukamauchi F, Kito S. Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochem Int 1996;29:435-42.
68 Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-40.
69 Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder. Arch Gen Psychiatry 2003;60:681-90.
70 Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56.
71 Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003:325-37.
72 Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
73 Wolf W. DU-127090 Solvay/H Lundbeck. Curr Opin Investig Drugs 2003;4:72-6.
74 Orsini C, Koob GF, Pulvirenti L. Dopamine partial agonist reverses amphetamine withdrawal in rats. Neuropsychopharmacology 2001;25:789-92.
75 Pulvirenti L, Koob GF, Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci 1994;15:374-9.
76 Pulvirenti L, Balducci C, Piercy M, Koob GF. Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther 1998;286:1231-8.
77 Weissenborn R, Deroche V, Koob GF, Weiss F. Effects of dopamine agonists and antagonists on cocaine-induced operant responding for a cocaine-associated stimulus. Psychopharmacology (Berl) 1996;126:311-22.
78 Izzo E, Orsini C, Koob GF, Pulvirenti L. A dopamine partial agonist and antagonist block amphetamine self-administration in a progressive ratio schedule. Pharmacol Biochem Behav 2001;68:701-8.
79 Sibole JM, Matea PJ, Krall CM, McDougall SA. Effects of a partial dopamine D(2)-like agonist on the cocaine-induced behavioral sensitization of preweanling rats. Pharmacol Biochem Behav 2003;76:27-34.
80 Withers NW, Pulvirenti L, Koob GF, Gillin JC. Cocaine abuse and dependence. J Clin Psychopharmacol 1995;15:63-78.
81 Pulvirenti L, Koob GF. Lisuride reduces psychomotor retardation during withdrawal from chronic intravenous amphetamine self-administration in rats. Neuropsychopharmacology 1993;8:213-8.
82 Barr AM, Phillips AG. Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 1999;141:99-106.
83 Barr AM, Fiorino DF, Phillips AG. Effects of withdrawal from an escalating dose schedule of d-amphetamine on sexual behavior in the male rat. Pharmacol Biochem Behav 1999;64:597-604.
84 Bono G, Balducci C, Richelmi P, Koob GF, Pulvirenti L. Dopamine partial receptor agonists reduce ethanol intake in the rat. Eur J Pharmacol 1996;296:233-8.
85 Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804.
86 Filip V, Marsalek M, Halkova E, Karen P. Treatment of extrapyramidal side effects with terguride. Psychiatry Res 1992;41:9-16.
87 Olbrich R, Schanz H. An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J Neural Transm Gen Sect 1991;84:233-6.
88 Ranaldi R, Wang Z, Woolverton WL. Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys. Drug Alcohol Depend 2001;64:209-17.
89 Arnt J, Bogeso KP, Christensen AV, Hyttel J, Larsen JJ, ad Svendsen O. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers. Psychopharmacology (Berl) 1983;81:199-207.
90 Hjorth S, Carlsson A, Clark D, Svensson K, Wikstrom H, Sanchez D, et al. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology (Berl) 1983;81:89-99.
91 Hjorth S. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system. Acta Physiol Scand 1983;517(Suppl):1-52.
92 Svensson L, Ahlenius S, Suppression of exploratory locomotor activity by the local application of dopamine or l-noradrenaline to the nucleus accumbens of the rat. Pharmacol Biochem Behav 1983;19:693-9.
93 Clark D, Engberg G, Pileblad E, Svensson TH, Carlsson A, Freeman AS, et al. An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system. Naunyn Schmiedebergs Arch Pharmacol 1985;329:344-54.
94 Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, et al. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 1995;275:1355-66.
95 Lahti RA, Figur LM, Piercey MF, Ruppel PL, Evans DL. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol 1992;42:432-8.
96 Chio CL, Lajiness ME, Huff RM. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 1994;45:51-60.
97 Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A, Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm Gen Sect 1992;88:165-75.
98 Wetzel H, Hillert A, Grunder G, Benkert O. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry 1994;151:1499-502.
99 Tamminga CA, Schaffer MH, Smith RC, Davis JM. Schizophrenic symptoms improve with apomorphine. Science 1978;200:567-8.
100 Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry 1986;43:398-402.
101 Akunne HC, Zoski KT, Davis MD, Cooke LW, Meltzer LT, Whetzel SZ, et al. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects. Neuropharmacology 2000;39:1197-210.
102 Corbin AE, Meltzer LT, Ninteman FW, Wiley JN, Christoffersen CL, Wustrow DJ, et al. PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects. Neuropharmacology 2000;39:1211-21.
103 Rugsley TA, Davis MD, Akunne HC, Cooke LW, Whetzel SZ, MacKenzie RG, et al. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. J Pharmacol Exp Ther 1995;274:898-911.
104 Meltzer LT, Christoffersen CL, Corbin AE, Ninteman FW, Serpa KA, Wiley JN, et al. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects. J Pharmacol Exp Ther 1995;274:912-20.
105 Sramek JJ, Eldon MA, Posvar E, Feng MR, Jhee SS, Hourani J, et al. Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. Psychopharmacol Bull 1998;34:93-9.
106 van Vliet LA, Rodenhuis N, Wikstrom H, Pugsley TA, Serpa KA, Meltzer LT, et al. Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists. J Med Chem 2000;43:3549-57.
107 van Vliet LA, Rodenhuis N, Dijkstra D, Wikstrom H, Pugsley TA, Serpa KA, et al. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). J Med Chem 2000;43:2871-82.